Solid Biosciences SLDB
NASDAQ SLDB
$6.47 +0.07 (+1.17%)
As of: Oct 21, 2026 · 11:41 AM EDT

Solid Biosciences (SLDB) Current Deferred Revenue (2020 - 2022)

Updated

Solid Biosciences' Current Deferred Revenue was $6.17 million in Q1 2022, down 42.1% from $10.66 million a year earlier and down 23.6% from the prior quarter.

Analysis

Solid Biosciences (SLDB) Current Deferred Revenue (2020 - 2022) Analysis & Trends

At the end of FY2021, Current Deferred Revenue at Solid Biosciences came in at $8.08 million, down 22.0% from FY2020.

  • In earlier years, Current Deferred Revenue was $10.36 million in FY2020.
  • Per Business Quant data, SLDB's Current Deferred Revenue in the three quarters before Q1 2022 was $8.08 million (Q4 2021), $8.87 million (Q3 2021) and $10.05 million (Q2 2021).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn
10 Solid Biosciences 931.82 Mn -250.53 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 6.17 Mn
Dec 31, 2021 8.08 Mn
Sep 30, 2021 8.87 Mn
Jun 30, 2021 10.05 Mn
Mar 31, 2021 10.66 Mn
Dec 31, 2020 10.36 Mn
API Access

Solid Biosciences Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=SLDB&period=max&api_key=YOUR_API_KEY